24 Sep 2021 11:10
AIM WINNERS & LOSERS: In The Style shares shredded by profit warning
AIM WINNERS & LOSERS: In The Style shares shredded by profit warning
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Imperial Innovations Group Share News (IVO)
IVO Share
Price
IVO Share
News
IVO Share
Chat
IVO Share
Trades
IVO
Live RNS
IVO Share
Charts
IVO Broker
Ratings
IVO Directors
Deals
IVO Financial
Diary
IVO
Fundamentals
IVO Short
Positions
IVO
Media
Imperial Innovations Group Information
- There is currently no data for IVO
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Imperial Innovations celebrates Cell Medica collaboration
Fri, 17th Jun 2016 15:58
(ShareCast News) - Imperial Innovations celebrated success at one of its investee companies on Friday, noting the announcement from Cell Medica of an exclusive licensing agreement and co-development partnership with the Baylor College of Medicine to create next-generation cellular immunotherapy products for the treatment of cancer.The AIM-traded firm said Cell Medica is a cellular immunotherapy company, focused on the development, manufacture and marketing of cell-based therapeutics for the treatment of cancers and infectious disease.As at 31 January, Imperial had a 27% interest in Cell Medica - a net fair value of £21m.Imperial's board said the new collaboration is expected to generate a significant number of new products for Cell Medica's cellular immunotherapy pipeline.It added that it provides the company with an exclusive license over several Baylor cell and gene technologies and an option to license new products introduced into the co-development partnership by Baylor's leading research teams in the field of genetically engineered immune cells."This collaboration with Baylor College of Medicine will place Cell Medica at the forefront of new product concepts for CAR-modified immune cells," said Cell Medica CEO Gregg Sands."Baylor's leading research capability in this field should add significantly to our pipeline of high value products targeting cancer types that do not respond to conventional treatments."Russ Cummings, CEO at Imperial Innovation, said the new agreement accelerates Cell Medica's ambitious growth plans and broadens its cellular immunotherapy pipeline and US footprint."It is an important step forward in its strategy to become a world-leader in cell therapy, leveraging its scientific and manufacturing base," he said."To date Cell Medica has raised more than £72m."With the on-going support of a strong group of investors, the business is ideally positioned to capitalise on the market opportunity for next-generation products which harness the human immune response to fight cancer," Cummings explained.
More News
5 Jan 2017 16:45
Imperial Innovations completes quick-change to Touchstone
(ShareCast News) - Imperial Innovations Group announced on Thursday that, further to the shareholder approval received at its AGM on 21 November 2016, the change of the company's name to Touchstone Innovations took effect on 4 January. The AIM-traded firm added that, with effect from 0800 GMT on Thu
Read more28 Oct 2016 14:18
Imperial Innovations to change name to 'Touchstone'
(ShareCast News) - Imperial Innovations Group announced on Friday that at its annual general meeting on 21 November, it will be seeking shareholder approval to change the name of the company to Touchstone Innovations. The AIM-traded group was originally formed as the technology transfer office for I
Read more24 Oct 2016 15:04
Imperial Innovations celebrates investment momentum
(ShareCast News) - Imperial Innovations Group noted on Monday that its portfolio company, Veryan Medical, has completed enrolment into the MIMICS-2 clinical study of its BioMimics 3D Self-Expanding Stent System. The AIM-traded firm said the MIMICS-2 study is a prospective, multicentre, interventiona
Read more13 Oct 2016 08:36
Imperial Innovations' increases investments as pre-tax loss widens
(ShareCast News) - Imperial Innovations' annual pre-tax loss widened while the technology commercialisation and investment company increased investments across its business with universities and a joint venture. For the year ended 31 July, the pre-tax loss widened to £63.1m from £15.1m, last year, w
Read more6 Oct 2016 15:15
6 Oct 2016 15:15
Imperial Innovations shares up on portfolio company progress
(ShareCast News) - Imperial Innovations Group updated the market on Thursday, noting that its portfolio company TopiVert Pharma has announced that the first patients have been dosed in its Phase IIa proof-of-concept study to evaluate the safety, tolerability and efficacy of a rectal formulation of T
Read more3 Oct 2016 15:20
Imperial Innovations sells Permasense portfolio business
(ShareCast News) - AIM-listed Imperial Innovations has sold its portfolio company Permasense to Fortune 500 company Emerson Electric for an initial consideration of £30.6m in cash. Further amounts of up to £10m may be paid in addition, subject to the Permasense business achieving certain performance
Read more21 Sep 2016 12:23
Imperial Innovations invests £5.1m in new biotech start-up
(ShareCast News) - AIM-listed technology investor Imperial Innovations invested £5.1m in Artios Pharma, a new biotech start-up launched on Wednesday. Imperial Innovations contributed £5.1m to the £25m series A funding round, giving it a 14.9% interest in the new Cambridge- based company. Artios, wh
Read more19 Aug 2016 09:23
Cambridge University innovation investor raises 75 million pounds
LONDON, Aug 19 (Reuters) - Cambridge Innovation Capital, which commercializes technology and healthcare research from Cambridge University, has raised 75 million pounds ($98 million) from investors, including for the first time Woodford Investment Management. CIC, founded in 2013, has alrea
Read more